Form 4: Invivyd CCO Sells Shares Post-RSU Vesting

Invivyd's Chief Commercial Officer, Timothy Edward Lee, sold shares to cover tax obligations following the vesting of restricted stock units, as part of a pre-arranged 10b5-1 plan.

Summary

• Timothy Edward Lee, Invivyd's Chief Commercial Officer, acquired 99,000 shares of common stock on August 15, 2025, through the vesting of Restricted Stock Units (RSUs).
• Following the RSU vesting, Lee sold a total of 49,656 shares of Invivyd common stock over two days to satisfy tax withholding obligations.
• On August 18, 2025, 20,013 shares were sold at a weighted average price of $0.6502 per share.
• On August 19, 2025, an additional 29,643 shares were sold at a weighted average price of $0.5666 per share.
• These sales were non-discretionary "sell-to-cover" transactions executed under a Rule 10b5-1 plan adopted on February 20, 2025.
• The reported ownership includes 10,000 shares acquired through the Company's Employee Stock Purchase Program.
• After these transactions, Timothy Edward Lee beneficially owns 59,344 shares of Invivyd common stock directly.
• Lee also holds 201,000 Restricted Stock Units (RSUs) which vest over an eighteen-month period, with one-third vesting every six months from the grant date of February 15, 2025.

Sentiment

Score: 6

Explanation: The filing reports routine executive equity transactions, specifically the vesting of Restricted Stock Units and subsequent "sell-to-cover" sales for tax obligations under a pre-arranged 10b5-1 plan. This is a standard event and does not indicate a change in company fundamentals or executive sentiment, though the declining sale price is noted.

Positives

• Vesting of 99,000 Restricted Stock Units indicates continued service and performance by a key executive.
• The transactions were executed under a pre-arranged Rule 10b5-1 plan, indicating a planned and non-discretionary sale for tax purposes rather than a discretionary sale based on market outlook.
• Inclusion of 10,000 shares acquired through the Employee Stock Purchase Program demonstrates ongoing participation in company equity programs.

Negatives

• The sale of 49,656 shares by a Chief Commercial Officer, even for tax purposes, reduces the executive's direct ownership stake in the company.
• The weighted average sale price for the August 19, 2025, transaction ($0.5666) was lower than the August 18, 2025, transaction ($0.6502), indicating a declining price during the sale period.

Risks

• No specific company-wide risks are mentioned in this Form 4 filing. The primary risk related to this transaction is the potential for market perception of insider selling, even if for tax purposes.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the vesting schedule of the remaining Restricted Stock Units.

Industry Context

This Form 4 filing reflects a routine executive compensation event (RSU vesting and sell-to-cover) common across publicly traded companies, particularly in the biotechnology or pharmaceutical sector where equity compensation is a significant component of executive pay. It does not provide broader industry-specific insights or trends.

Comparison to Industry Standards

• The transactions are standard for executive equity compensation and tax management. Sell-to-cover transactions under Rule 10b5-1 plans are a common practice for executives to manage tax liabilities arising from equity awards. No specific comparable companies, projects, or results are mentioned in the filing to allow for a detailed comparison.

Corporate Governance

Related Party Transactions

• The filing details transactions by a company officer (Timothy Edward Lee) which are considered related party transactions in the context of executive compensation and equity ownership.

Stakeholder Impact

• Shareholders: The sale of shares by a CCO, even for tax purposes, slightly reduces the executive's direct alignment with shareholder interests, though the 10b5-1 plan mitigates negative interpretation. The vesting of RSUs indicates continued executive commitment.
• Employees: The RSU vesting and ESPP acquisition highlight the company's equity compensation programs, which can be a positive for employee retention and motivation.

Next Steps

• Remaining Restricted Stock Units will continue to vest over an eighteen-month period, with one-third vesting every six months following the grant date of February 15, 2025, subject to continuous service.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events, specifically the vesting of Restricted Stock Units and subsequent 'sell-to-cover' transactions for tax purposes under a pre-arranged 10b5-1 plan. Such transactions are common and do not typically signal a change in the company's fundamental outlook or the executive's confidence. While the executive's direct shareholding decreases, the underlying RSU vesting and ESPP participation are positive indicators of continued engagement. Without additional information on the company's financial performance or strategic direction, this filing alone does not warrant a change in investment posture.

Keywords

Invivyd, IVVD, Timothy Edward Lee, Chief Commercial Officer, Form 4, SEC filing, insider trading, stock sale, RSU vesting, Rule 10b5-1, sell-to-cover, executive compensation, equity